Quantcast
Home / Practice Areas / Personal Injury and Tort / J&J unit settles state Risperdal claims for $181M

J&J unit settles state Risperdal claims for $181M

Johnson & Johnson has agreed to pay a record $181 million to settle claims brought by New York and 36 other states that the company’s Janssen Pharmaceuticals unit improperly marketed Risperdal and other anti-psychotic drugs for “off-label” uses.